Perdagangan Vir Biotechnology VIR

VirBiotechnology diagram langsung

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tampilkan lebih banyak
Alec Malloy 2025 Mei 29, 16:00

Tempus stock: TEM stock drops after short seller questions revenue sources

Stocks
Frances Wang 2025 Mei 29, 16:00

Gap Lists Tariff Costs: Gap Stock Falls After Retailer Forecasts Flat Sales

Stocks
Tommy Yap 2025 Mei 29, 16:00

Morning Note: Trump Tariff Swings; Tokyo Inflation Spikes; US PCE Eyed

Morning Note
Ghko B 2025 Mei 28, 16:00

Tariff news update: US trade court blocks Trump “liberation day” tariffs

Stocks
Frances Wang 2025 Mei 28, 16:00

Crypto market today: How high will Bitcoin get this year?

Cryptocurrencies
Frances Wang 2025 Mei 28, 16:00

Joby Stock Is Climbing Today: what’s going on with Joby Aviation?

Stocks
Tommy Yap 2025 Mei 28, 16:00

Morning Note: USD Jumps on Tariff Block; NVIDIA's Strong Q1; Costco Earnings Due

Morning Note Forex Tech
Frances Wang 2025 Mei 27, 16:00

GOOGL Share Price Analysis: Why Alphabet Stock Is Up Today?

Stocks

Info

Spread

0.03

Spread (%)

0.6110 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar tutup

Senin

13:31 - 19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Kamis

13:31-19:59

Jumat

13:31-19:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

717455232

Saham yang Beredar

138238000

Tanggal Penghasilan (Berikutnya)

0000-00-00

Hasil Div

Tanggal Non-Dividen

Proyeksi tingkat dividen tahunan

0

Proyeksi hasil dividen tahunan

0

EPS

-4.61

Pelajari lebih lanjut tentang instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tampilkan lebih banyak
Trustpilot